Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience

Abstract Background Recent observations suggest a lack of humoral response after SARS-CoV-2 vaccination in multiple sclerosis (MS) patients treated with fingolimod or ocrelizumab Objectives To assess serological response to SARS-CoV-2 vaccination in MS patients receiving these disease-modifying treatments (DMTs) in a real-life setting. Methods Retrospective clinical data collection from MS patients followed at San Raffaele Hospital MS Centre (Milan, Italy). All patients treated with fingolimod or ocrelizumab who had received a complete anti-COVID-19 vaccination course, with no clinical history suggestive of previous SARS-CoV-2 infection and with an available post-vaccination serological assay obtained at least 14 days after vaccination completion were considered for the study. Results We collected data from 32 MS patients, 16 treated with fingolimod and 16 receiving ocrelizumab. Among the fingolimod group 10 patients (62.5%) had a positive serological response after vaccination and among ocrelizumab-treated patients a positive serological test was found in six cases (37.5%). No relation between serological response and clinical features (i.e., treatment duration, time between vaccination and last treatment dose, and white blood cells count) was identified. Conclusions Our initial real-life experience suggests a variable antibody production in MS patients receiving these DMTs. At present, there are no sufficient data to do not recommend anti-SARS-CoV-2 vaccine in these patients.

Download Full-text

Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients

The Journal of Clinical Pharmacology ◽

10.1002/jcph.670 ◽

2015 ◽

Vol 56 (7) ◽

pp. 845-851 ◽

Cited By ~ 8

Author(s):

Damiano Paolicelli ◽

Vita Direnzo ◽

Alessia Manni ◽

Mariangela D'Onghia ◽

Carla Tortorella ◽

...

Keyword(s):

Multiple Sclerosis ◽

Real Life ◽

Real Life Setting ◽

Multiple Sclerosis Patients ◽

Term Data

Download Full-text

Vaccination opportunities in multiple sclerosis patients treated with cladribine tablets

Current Neuropharmacology ◽

10.2174/1570159x20666211217160451 ◽

2021 ◽

Vol 20 ◽

Author(s):

Lucia Moiola ◽

Agostino Riva ◽

Ferdinando Nicoletti ◽

Antonio Uccelli ◽

Marco Salvetti ◽

...

Keyword(s):

Multiple Sclerosis ◽

Immune System ◽

Mechanism Of Action ◽

Vaccination Campaign ◽

Humoral Response ◽

Focused Attention ◽

Vulnerable Patients ◽

Mass Vaccination Campaign ◽

Multiple Sclerosis Patients ◽

Vaccination Campaigns

: The COVID-19 pandemic and the mass vaccination campaign highlighted the situation of the most vulnerable patients. In this work, we focused attention on patients who have Multiple Sclerosis (MS), particularly in treatment with cladribine tablets, trying to understand if and when it is possible to administer the vaccine successfully. Considering the innovative topic, we reviewed the existing literature with an analysis of the experiences also related to other vaccinations, including influenza and VZV, and very recent data from countries with vaccination campaigns already advanced. Overall, we have taken into account the mechanism of action, the pharmacokinetic/pharmacodynamic of cladribine and the changes in the immune system after its administration, together with the preliminary data about the humoral response to influenza, VZV and SARS-CoV-2 vaccinations in cladribine treated patients. In conclusion, data showed that the use of cladribine tablets seems to permit flexibility regarding vaccination timing and we suggest that vaccination in those patients should be safe and effective.

Download Full-text

Real-life experience with fampridine (Fampyra®) for patients with multiple sclerosis and gait disorders

Neurorehabilitation ◽

10.3233/nre-161361 ◽

2016 ◽

Vol 39 (2) ◽

pp. 301-304 ◽

Cited By ~ 8

Author(s):

Yara Dadalti Fragoso ◽

Tarso Adoni ◽

Soniza Vieira Alves-Leon ◽

Samira Luisa Apostolos-Pereira ◽

Amilton Antunes Barreira ◽

...

Keyword(s):

Multiple Sclerosis ◽

Life Experience ◽

Real Life ◽

Gait Disorders

Download Full-text

Natalizumab modulates the humoral response against HERV-Wenv73–88 in a follow-up study of Multiple Sclerosis patients

Journal of the Neurological Sciences ◽

10.1016/j.jns.2015.07.007 ◽

2015 ◽

Vol 357 (1-2) ◽

pp. 106-108 ◽

Cited By ~ 7

Author(s):

Giannina Arru ◽

Elisa Caggiu ◽

Stefania Leoni ◽

Giuseppe Mameli ◽

Maura Pugliatti ◽

...

Keyword(s):

Multiple Sclerosis ◽

Humoral Response ◽

Follow Up Study ◽

Multiple Sclerosis Patients

Download Full-text

Association of Mycobacterium avium subsp. paratuberculosis and SLC11A1 polymorphisms in Sardinian multiple sclerosis patients

The Journal of Infection in Developing Countries ◽

10.3855/jidc.2737 ◽

2013 ◽

Vol 7 (03) ◽

pp. 203-207 ◽

Cited By ~ 13

Author(s):

Davide Cossu ◽

Speranza Masala ◽

Eleonora Cocco ◽

Daniela Paccagnini ◽

Stefania Tranquilli ◽

...

Keyword(s):

Multiple Sclerosis ◽

Autoimmune Disease ◽

Mycobacterium Avium ◽

Humoral Response ◽

Mycobacterium Avium Subsp ◽

Nucleotide Polymorphisms ◽

Specific Pcr ◽

Pcr Rflp ◽

Mycobacterium Avium Subsp Paratuberculosis ◽

Multiple Sclerosis Patients

Introduction: Recent findings propose that Mycobacterium avium subsp. paratuberculosis (MAP) infection could act as risk factor in favoring multiple sclerosis (MS) progression. SLC11A1 is a gene associated with mycobacterial survival in the host and it may be involved in the induction and maintenance of autoimmune disease. Methodology: In this preliminary study, 100 MS patients and 100 healthy controls (HCs) from Sardinia were enrolled. Eight single nucleotide polymorphisms (SNPs) in the SLC11A gene were searched by PCR RFLP-genotyping. IS900 specie specific PCR was undertaken to search for MAP presence. Indirect ELISA was performed to asses if MS patients displayed a stronger humoral response against MAP2694 protein compared to the HCs. Results: Only rs2276631 SNP was associated with MS. MAP DNA was detected in 23 out of 100 MS patients (23%) and in 7 out of 100 HCs (7%). A strong humoral response against MAP2694 protein was detected in 36% of MS patients and only in 3% of HCs. A correlation between ELISA sero-positivity and the rs2276631 SNP was also found. Conclusion: Our preliminary results suggest that the Sardinian population might be prone to develop autoimmune disease due to polymorphisms in immunomodulating the SLC11A1 gene, which is important in the immune response against intracellular bacteria such as MAP.

Download Full-text

Comparative effectiveness of dimethyl fumarate in Multiple Sclerosis

10.21203/rs.3.rs-321622/v1 ◽

2021 ◽

Author(s):

Pauline Bosco-Levy ◽

Marc Debouverie ◽

Bruno Brochet ◽

Céline Louapre ◽

Elisabeth Maillard ◽

...

Keyword(s):

Multiple Sclerosis ◽

Negative Binomial ◽

Real Life ◽

Logistic Models ◽

Negative Binomial Regression ◽

Dimethyl Fumarate ◽

Population Based ◽

Disability Progression ◽

Real Life Setting ◽

Using Data

Abstract Objectives: To assess the effectiveness of dimethyl fumarate (DMF) on annual rate of relapse (ARR) and disability progression in multiple sclerosis (MS) compared to injectable immunomodulators (IMM), teriflunomide (TERI) and fingolimob (FTY), in real life setting. Methods: A population-based cohort study was conducted using data of the French nationwide claims database, SNDS. All patients initiating IMM, TERI, FTY or DMF between July 1, 2015 and December 12, 2017, with 4.5 years of database history and 1 to 3.5 years of follow-up were included in this study. DMF patients were 1:1 matched to IMM, TERI or FTY using a high dimensional Propensity Score. Negative binomial regression and a regression logistic models were used to estimate the relative risk (RR ± [95% CI]) of ARR and the Odds Ratio (OR ± [95% CI]) of disability progression, respectively. Results: Overall, 9 304 subjects were identified: 29.0% initiated DMF, 33.2% TERI, 5.6% FTY and 32.2% an IMM. The matched cohorts consisted of 1779 DMF- IMM, patients, 1679 DMF-TERI patients, and 376 DMF-FTY patients. DMF significantly reduced ARR compared to IMM (RR 0.72 [0.61 - 0.86]) and TERI (0.81 [0.68 - 0.96]). The risk of the progression of MS specific disability was not significantly different for any matched cohorts.Interpretation: DMF is associated with lower risk of relapse for patients with RRMS than other first-line RRMS agents (TERI and IIM).

Download Full-text